Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002539-25-IT

Enrollment

Registered

2005-02-16

Start date

2004-12-10

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second-line chemotherapy in advanced non small cell lung cancer MedDRA version: 6.1 Level: PT Classification code 10059515

Interventions

Trade Name: ELOXATIN*IV 1 FL 50 MG Product Name: NA Product Code: NA Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Oxaliplatin CAS Number: 61825-94-3 Concentration unit: mg/m2 milligr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026